



IntelliBio

Gen AI-platform for research tasks at biotechs

Your Bridge between Gen AI productivity and
Life Science Innovation.

Our mission:

Significant R&D
productivity gains
using generative AI



Problem

Generative AI will **transform R&D** workflows, problem solving by researchers, and discovery & design.

But:

1 Biotech SMEs are **constrained on resources** to develop & integrate.

2 **Data quality** is a concern for 80% of biotech teams¹.

3 The **security** of Cloud-based AI is a red flag for 80% of biotechs².

4 Generic AI applications **do not translate well** to biotech use cases.

Solution

Empowering biotech teams with a **tailored Gen AI suite** to break through constraints, streamline workflows, and unlock unprecedented productivity with intelligent automation and AI-driven insights.



Time-Saving Workflow AI

Specialized for
research tasks



Embedding & SLMs

for
rapid, precise
contextual
understanding



Secure On-Premise AI

Protects IP and
secures privacy



Collaborative dashboard

Enhances team
efficiency

Market Validation

- Value per customer validated at >€30,000 per year
- Validated price first offering at €1,000 (single use case)

Current validation in the market:

- Current offering: IntelliBio has developed 3x AI agents (MVP)
- Sales; Grant Genie at €1,500 (3 sales with 50% discount)

Paying customers:



Market Size

The value of Generative AI within biotech will shortly exceed the (€38B) SaaS for biotech market.



Gen AI-driven **productivity** to add €21B value to biotech by 2025



Initial target market is 2,300 **biotech SMEs** in Europe.



Value per customer validated at >€30,000 per year.

Product

"Our AI-powered platform leverages embeddings and Small Language Models (SLMs) to deliver secure, on-premise solutions that empower biotech teams to accelerate research, automate workflows, and unlock faster innovation with unparalleled productivity."



Business Model

IntelliBio intends to operate as a AI-a-a-S business.

- **Launch Grant Genie:** Establish market presence & initial revenue.
- **Develop On-Prem PoC:** Validate with biotech SMEs.
- **Expand offering of AI agents:** Develop modular AI capabilities.
- **Scale Operations:** Use follow-up funding to expand products.
- **Build AI Suite:** Offer €30k–€100k/year modular solutions.

Competition

By addressing gaps in data privacy, integration complexity, and cost-effectiveness, our AI-powered platform provides secure solutions with customizable tools designed for their unique research needs.

Advantages

- Comprehensive all-in-one platforms (e.g. Benchling).
- Foundational model R&D (e.g., DeepMind).
- Cloud Accessibility & Seamless remote collaboration.

Disadvantages

- Data Privacy Concerns: Limited security for sensitive data.
- High Costs: Expensive for smaller biotech firms.
- Rigid AI Tools: Limited customization for workflows.

Our Team



Dr. Boaz van Driel CEO
& co-founder



Leonard Gonsalves CTO
& co-founder



Enrico Maset
Advisor & Partner

Our Founding Team:

Bridging Life Science Innovation
with Technological Excellence

Our Partner:

Leveraging funding
for rapid growth.



Thank You

Further contact:

Boaz van Driel, PhD | CEO IntelliBio BV

boazceo@intellibio.tech

+31 6 53715300

Testimonials

Our customers recognize our long-term potential and short-term value.

“You need a respectable biotech to work with as launching customer, I think my new venture Gyes BV can be that.”

– Biotech CEO with >€1B IPO

“... Profs here [] all are very excited to try [Grant Genie] ...!”

- Neuroscience prof. at ETH (Swiss)

“That is really good quality, only needed a few edits.”

– Fred Vaz, Director metabolomics lab